Postmenopausal women at high risk for breast cancer have a new option for chemoprevention, which appears to be safer and more effective than SERMs. br / iMedscape Medical News/i
A class of genetic mutations discovered in children with high-risk acute lymphoblastic leukemia gives hope for a new treatment approach; drugs targeting the defect are already in clinical development. Medscape Medical News
Toxicity has led to the development of breast cancer treatment regimens featuring a taxane without an anthracycline, but biomarkers may help identify those who can benefit from both. Future Oncology
Differences in receptor expression in nodal tumor tissue and in primary breast cancer might be a reason for the failure of adjuvant therapy. Medscape Medical News
